Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Epithelium-specific deletion of TGF-β receptor type II protects mice from bleomycin-induced pulmonary fibrosis.

Li M, Krishnaveni MS, Li C, Zhou B, Xing Y, Banfalvi A, Li A, Lombardi V, Akbari O, Borok Z, Minoo P.

J Clin Invest. 2011 Jan;121(1):277-87. doi: 10.1172/JCI42090. Epub 2010 Dec 6.

2.

The pathogenesis of systemic sclerosis.

Katsumoto TR, Whitfield ML, Connolly MK.

Annu Rev Pathol. 2011;6:509-37. doi: 10.1146/annurev-pathol-011110-130312. Review.

PMID:
21090968
3.

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Ley B, Collard HR, King TE Jr.

Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40. doi: 10.1164/rccm.201006-0894CI. Epub 2010 Oct 8. Review.

PMID:
20935110
4.

The polarization of immune cells in the tumour environment by TGFbeta.

Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P.

Nat Rev Immunol. 2010 Aug;10(8):554-67. doi: 10.1038/nri2808. Epub 2010 Jul 9. Review.

5.

Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence.

Christmann RB, Wells AU, Capelozzi VL, Silver RM.

Semin Arthritis Rheum. 2010 Dec;40(3):241-9. doi: 10.1016/j.semarthrit.2010.03.002. Epub 2010 May 21. Review.

PMID:
20494406
6.

Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis.

Aden N, Nuttall A, Shiwen X, de Winter P, Leask A, Black CM, Denton CP, Abraham DJ, Stratton RJ.

J Invest Dermatol. 2010 Sep;130(9):2191-200. doi: 10.1038/jid.2010.120. Epub 2010 May 6.

7.

Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease.

Veraldi KL, Hsu E, Feghali-Bostwick CA.

Curr Rheumatol Rep. 2010 Feb;12(1):19-25. doi: 10.1007/s11926-009-0071-8. Review.

PMID:
20425529
8.

Does chronic microaspiration cause idiopathic pulmonary fibrosis?

Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TE Jr.

Am J Med. 2010 Apr;123(4):304-11. doi: 10.1016/j.amjmed.2009.07.033. Review.

9.

Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis.

Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, Engelhardt JF, Liu X, White ES, Thannickal VJ, Moore BB, Christensen PJ, Simon RH.

Am J Respir Crit Care Med. 2010 Feb 1;181(3):254-63. doi: 10.1164/rccm.200810-1615OC. Epub 2009 Oct 22.

10.

A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.

Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, Whitfield ML.

J Invest Dermatol. 2010 Mar;130(3):694-705. doi: 10.1038/jid.2009.318. Epub 2009 Oct 8.

11.

Molecular subsets in the gene expression signatures of scleroderma skin.

Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, Whitfield ML.

PLoS One. 2008 Jul 16;3(7):e2696. doi: 10.1371/journal.pone.0002696. Erratum in: PLoS ONE. 2008;3(10). doi: 10.1371/annotation/05bed72c-c6f6-4685-a732-02c78e5f66c2.

12.

Characterization of the innate immune response to chronic aspiration in a novel rodent model.

Appel JZ 3rd, Lee SM, Hartwig MG, Li B, Hsieh CC, Cantu E 3rd, Yoon Y, Lin SS, Parker W, Davis RD.

Respir Res. 2007 Nov 27;8:87.

13.

Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation.

Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, Simon KJ, Hahm K, Allaire NE, Rinaldi NJ, Goyal J, Feghali-Bostwick CA, Matteson EL, O'Hara C, Lafyatis R, Davis GS, Huang X, Sheppard D, Violette SM.

Am J Respir Crit Care Med. 2008 Jan 1;177(1):56-65. Epub 2007 Oct 4.

PMID:
17916809
14.

Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis.

Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z, Devitt ML, Horan GS, Weinreb PH, Lukashev ME, Violette SM, Grant KS, Colarossi C, Formenti SC, Munger JS.

Am J Respir Crit Care Med. 2008 Jan 1;177(1):82-90. Epub 2007 Oct 4.

15.
16.

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.

Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE Jr, Golden JA.

Respir Med. 2008 Jan;102(1):150-5. Epub 2007 Sep 5.

17.

TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease.

Willis BC, Borok Z.

Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L525-34. Epub 2007 Jul 13. Review.

PMID:
17631612
18.

Changes in causes of death in systemic sclerosis, 1972-2002.

Steen VD, Medsger TA.

Ann Rheum Dis. 2007 Jul;66(7):940-4. Epub 2007 Feb 28.

19.

Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.

Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B.

Arthritis Rheum. 2007 Jan;56(1):334-44.

20.

Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.

Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen Fv, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR; Cat-192 Study Group; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2007 Jan;56(1):323-33.

Supplemental Content

Support Center